penhome
23 Jan 2017
Re: Beginning to recover I posted in December that I thought this had bottomed. It is now breaking out above November consolidation. Daily RSI is only at 60 and MACD still hasn't crossed above zero, so the move up could have some way to go. Breakout needs confirmation from daily closes. Intraday highs are not enough.[link]
theprior
23 Jan 2017
Proactive [link]
theprior
23 Jan 2017
Beginning to recover The pain of the Placing and subsequent sp collapse is finally beginning to ease and the patient is beginning to recover.Nursing should continue for a while but a full recovery is anticipated, leading to an Olympic style performance as phase 3 trials are published.TP
penhome
11 Jan 2017
Re: Bottomed. Probably I'm planning to buy a second tranche with closes above 26.5p and rising BB width.Still stopped at 22 on first tranche.
onedb1
11 Jan 2017
Re: Bottomed. Probably After my last trade am looking this to re-enter . Though I need that breakout feel . Always on my watch list as when they get it right the annual revenue projections are insane vis a vis the market cap . May take some time . Am on the sidelines for now
penhome
19 Dec 2016
Bottomed? This looks as if it has bottomed and now on the rise.[link] tranche bought at 25 with stop at 22 and initial target of 37.
JudahBenHur
21 Nov 2016
Re: Beaufort Securities note Our view: It's been painful, but at least it's finally been done! Motif has achieved its NASDAQ listing, through which the true value of iclaprim can now be recognised. Quite why the whole exercise has been so tricky for a Group that quite clearly own the rights to such a quite exception and advanced novel antibiotic, which has obvious US peers valued at a multiple of it's now paltry (pre-issue) valuation of £32.5m, is something of a mystery. Even on a post-issue basis, it is less than one-quarter that of Paratek Pharmaceuticals Inc., Motif's most obvious peer, which presently has a market cap of US$294m. Motif management now, quite clearly, must climb back up the ladder of investor credibility. But given the quite exception profile of iclaprim, that should not be too difficult. And with the net proceeds of the fundraising expected to be at least US$20.5 million, this will be sufficient capital to fund (i) the expenses to conducting the molecule's two Phase 3 clinical trials for the treatment of ABSSSI, including the completion of the REVIVE-1 trial; and (ii) working capital, general and administrative expenses, research and development expenses, and other general corporate purposes. The Board notes it will require additional funds to complete the REVIVE-2 trial, for which it suggests opportunity to raise the additional capital through public or private financings and/or other partnering opportunities. Given, however, the fact that patient enrollment for REVIVE-1 has exceeded projections and data readout is now expected in the second quarter of 2017, the point at which big pharma normally comes to the negotiating table, it would be realistic to expect partnering opportunities to present themselves by then. Typically, these would be in the form of an up-front lump sum, followed by milestone/royalty payments on route to commercialisation, sufficient to plug the near-term funding gap. Beaufort strongly believes in the potential for iclaprim, whose platform of prospective indications creates opportunity way beyond those already identified. Recognition of this should herald a significant re-rating for the shares and those shareholders who subscribed the European Offer will, in due course, be seen to have bagged a bargain. Given that the exercise price of the attached 5-year warrants of 32.2p will likely provide some near-term resistance for the shares, Beaufort recommends using this and the improved liquidity thus created in order to build up underweight positions. Beaufort retains a Speculative Buy rating on Motif Bio.
colebrooke1
20 Nov 2016
Dr Gary Waanders at Zeus Capital Interview Dr Gary Waanders of Zeus Capital from April 2016.Great summation of the potential here.[link]
Elster
18 Nov 2016
IPO but at what a miserable price What a mess they have made. No excuse .
penhome
16 Nov 2016
Re: IPO article in previous post Reading this first paragraph again:"Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, lowered the proposed deal size for its upcoming IPO on Monday."I read this as saying the upcoming IPO was on Monday. It might also mean the proposed deal size was lowered on Monday. Either way, they're expecting the price to be set sometime this week. This is probably why we are now down to 33p
penhome
16 Nov 2016
IPO Monday? According to the following article published on the 14th November, MFTB is expected to price the IPO this week:[link]
JudahBenHur
14 Nov 2016
Re: Motif bio Good observation RipleyNice rise today, Nasdaq listing should hopefully be on?No smoke without fire.RegardsJudah
JudahBenHur
11 Nov 2016
Re: IPO back on Can't see MTFB not raising the funds, decided to take a holding.When funds have been secured this should rise somewhat.
Ripley94
10 Nov 2016
Re: Motif bio Big fall since October now pick up for 34 p
penhome
08 Nov 2016
Re: IPO back on No more news as far as I am aware.I guess the next news will be either an RNS or an update on SEC filings.
